Valentin Garcia Gutiérrez, MD, PhD, Hospital Universitario Ramón y Cajal, Madrid, Spain, discusses the necessity to develop novel treatment strategies for patients with chronic myeloid leukemia (CML) who are resistant or intolerant to available tyrosine kinase inhibitors (TKIs), commenting on asciminib and novel TKIs currently under investigation, as well as the possibility to combine TKIs with other agents. This interview took place at the 24th Annual John Goldman Conference on Chronic Myeloid Leukemia (ESH CML) held in Mandelieu-La Napoule, France.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
Research funding, speaking engagements, ad boards: Novartis, BMS, Incyte, Pfizer